Gastroenterology 2017-11-21T20:49:22+00:00

Our Work in Gastroenterology

Targeted biologics, the recent emergence of innovative new oral therapies, and the arrival of biosimilars will continue to fuel monumental shifts in the way patients with auto-immune disorders are managed. More than ever, for both existing brands & pipeline products, future success will require a deep understanding of this complex and rapidly evolving landscape.

VIEW REPORTS OFFERED IN THIS AREA

Diseases Covered

Inflammatory Bowel Disorder, Crohn’s Disease, Ulcerative Colitis

Board of Advisors

Coming soon.

Advocacy Groups

The primary objectives of advocacy groups are to educate, advocate, collaborate, and improve the efficiency of services for individuals with diseases in gastroenterology and those who are close to them.

RECENT PUBLICATIONS

Takeda’s Entyvio Defends Share Against Janssen’s Stelara in the Crohn’s Disease Market, and Pressure in the Ulcerative Colitis Market May Heat Up in Early 2018 if Pfizer’s Xeljanz Secures an FDA Wina – November 21, 2017
>VIEW ARTICLE

US Gastroenterologists May Thwart Uptake of New Biosimilars, Such as Pfizer’s Inflectra and Merck/Samsung Bioepis’ Renflexis, by Choosing an Alternative TNF-Inhibitor, Such as AbbVie’s Humira – August 29, 2017
>VIEW ARTICLE

Pfizer’s Inflectra, Takeda’s Entyvio, and Janssen’s Simponi Projected to Gain Ground in the Increasingly Competitive Ulcerative Colitis Market – July 7, 2017
>VIEW ARTICLE

UPCOMING CONFERENCES

Advances in Inflammatory Bowel Diseases 2017
>LEARN MORE

HELPFUL LINKS

gastro journal logo
immunology journal logo